This Is Why You Need To Be Watching These 5 Canadian Cannabis Stocks

TM editors’ note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

Canadian cannabis companies continue to be one of the most attractive opportunities as investors aim to capitalize on this burgeoning growth opportunity.

We have been bullish on this sector for the last two years and our conviction level remains high as growth prospects look attractive for the coming years. The opportunity many of these cannabis producers are focused on is much bigger than just Canada and we are targeting companies focused on the global marijuana market.

Today, we have highlighted five company developments that investors need to be aware of. Over the coming months, we expect to see these companies continue to execute and investors should be monitoring these players.

Organigram Rallies After Health Canada Grants License

The market responded favorably to Organigram (OGI.V) (OGRMF) receiving an expanded cultivation license from Health Canada related to its previously announced Phase 2 expansion. This was a significant announcement and we remain bullish on the Canadian marijuana producer.

The Phase 2 expansion also includes significant improvements and efficiencies to the cultivation and processing systems. The scope of the amendment includes approval of the first ten of the new 23 three-level cultivation rooms as well as the entire perimeter of the expanded facility, approx. 150,000 sq. ft.

As a result of this approval, cannabis plants were moved into these new rooms on a rolling basis beginning on February 10th. The company will be in a position to begin staggered harvests from these new rooms by the third week of April.The remaining 13 rooms are expected to come on line by March 10th pending Health Canada approval.

With Organigram’s unique three-level grow system, the 23 planned cultivation rooms represent an additional 10,800 kg/year of production capacity increasing total capacity from approx. 5,200 kg/year to 16,000 kg/year. The Phase 3 expansion (expected to be complete in May) will increase Organigram’s production to 25,000 kg/annum. A fully-funded Phase 4 expansion (currently scheduled to start construction expected to commence in April) will bring production capacity to 65,000 kg/annum in three stages over the next two years.